Finally, cluster #6 (circulating tumor DNA) highlights the growing interest in liquid biopsy techniques for prognosis prediction and dynamic monitoring of gene mutation status in ALK-positive NSCLC during the last decade. The gene discussed is ALK; the disease is non-small cell lung carcinoma.